Doshi Dipal forfeited 8,724 Entrada Therapeutics shares at $7.14 per share on September 2, 2026, leaving the CEO with 517,290 shares. The updated ownership figure gives investors a current reference point for Dipal’s stake after the insider transaction.

Key Highlights

  • The transaction was priced at $7.14 per share.
  • Dipal owned 517,290 Entrada Therapeutics shares after the forfeiture.
  • Entrada Therapeutics identifies Dipal as its CEO and uses the symbol TRDA.

Doshi Dipal forfeited 8,724 shares of Entrada Therapeutics on September 2, 2026, in an insider transaction. The transaction was followed by a reported ownership balance of 517,290 shares for Dipal.

$7.14 Per-Share Insider Transaction

The filing reports the forfeiture at $7.14 per share. The record identifies Dipal as CEO of Entrada Therapeutics, Inc (NASDAQ: TRDA). and associates the company with the symbol TRDA. The transaction carries code F. Dipal’s post-transaction ownership was 517,290 shares of Entrada Therapeutics.